Adjuvant chemotherapy for resectable colon cancer Postoperative adjuvant chemotherapy for resectable colon cancer has attracted great attention.97 The choice of postoperative adjuvant therapy for patients with nonmetastatic colon cancer should be based on stage: 1. Stage I patients do not require any adjuvant therapy. 2. Low-risk stage II patients may be enrolled in clinical trials, observed without chemotherapy, or considered for adjuvant chemotherapy with capecitabine or 5-FU/LV. Based on the MOSAIC trial98-101 and the possible long-term sequelae with oxaliplatin, the panel concluded that the FOLFOX regimen is not suitable for adjuvant therapy in stage II patients without high-risk factors. 3. High-risk stage II patients, defined as those with poor prognosis, include: T4 (stage IIB, IIC), poor histological differentiation (grade 3/4, excluding MSI-H), vascular infiltration, nerve infiltration, intestinal obstruction, tumor site perforation, positive or unknown cut margins, insufficient safe distance to cut margins, and less than 12 lymph nodes sent for examination. Such patients may be considered for chemotherapy with 5-FU/LV, capecitabine, FOLFOX, capecitabine/oxaliplatin (CapeOx), or FLOX regimens.22,102 No chemotherapy for observation only is also an option, and the panel recommends 6 months of adjuvant chemotherapy after resection of the primary site in stage III patients.103 The regimens available are: oxaliplatin/5-FU/LV as standard therapy (mFOLFOX6, Level 1 evidence)98-101,104; oxaliplatin/5-FU infusion/LV (FLOX, Level 1 evidence)107; and capecitabine/oxaliplatin (CapeOX, Level 1 evidence)105,106. single-agent capecitabine108 or 5-FU/LV for patients who cannot use oxaliplatin.109-112 The study data do not support support the use of irinotecan-containing regimens for adjuvant irinotecan in the adjuvant chemotherapy of stage II or III colon cancer for the treatment of non-metastatic colon cancer. There are no NCCN guidelines for the treatment of small bowel and appendiceal adenocarcinoma, and the NCCN guidelines for colon cancer are available for the selection of systemic chemotherapy. For elderly patients ≥70 years of age with stage II/III colon cancer, the survival benefit of adding oxaliplatin to adjuvant chemotherapy has not been demonstrated. Bevacizumab is ineffective in adjuvant therapy for patients with stage II/III colon cancer, and there is even a trend to the contrary. Currently, there is no evidence to support the use of bevacizumab for postoperative adjuvant therapy in patients with stage II/III colorectal cancer.